search
Back to results

Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents (EryAdo)

Primary Purpose

Insulin Resistance, Glucose Tolerance, Body Composition

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Eryhtritol
Sucrose
Glucose
Fructose
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Insulin Resistance

Eligibility Criteria

14 Years - 55 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy adolescents
  • Aged 14-18 years
  • Normal weight (BMI between 15th and 85th percentile for age and gender)
  • Minimum weight of 45kg
  • Regular sugar consumption >25g/d

Exclusion Criteria:

  • Severe acute or chronic diseases
  • Pregnancy
  • Regular intake of prebiotics
  • Regular intake of probiotics
  • Regular intake of pro-/prebiotic foods
  • Antibiotics cure within 3 months preceding the present study
  • Substance abuse
  • Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German)
  • Participation in another study with investigational drug within the 30 days preceding and during the present study.
  • Pre-existing regular consumption (>1/week) of erythritol
  • Fructose-intolerance
  • Pre-existing diet (vegetarian, vegan, gluten-free, lactose-free, caloric restriction, etc.)

Sites / Locations

  • St. ClaraspitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Active Comparator

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Sucrose

Erythritol

EryClot-Pilot Erythritol

EryClot-Pilot Glucose

EryClot-Pilot Fructose

Arm Description

15 participants receive 25g sucrose per day during 5 weeks

15 participants receive 36g eryhtritol per day during 5 weeks

3 participants receive 50g erythritol dissolved in 300mL water once during the visit

3 participants receive 75g glucose dissolved in 300mL water once during the visit

3 participants receive 25g fructose dissolved in 300mL water once during the visit

Outcomes

Primary Outcome Measures

Insulin resistance
Insulin resistance as measured by the HOMA Index.
EryClot-Pilot Thrombocyte aggregation
Thrombocyte aggregation after consumption of test solution measured with a blood sample

Secondary Outcome Measures

Glucose tolerance: Insulin
Insulin levels during OGTT
Glucose tolerance: Glucose
Glucose levels during OGTT
Glucose tolerance: C-Peptide
C-peptide levels during OGTT
Glucose tolerance: Glucagon
Glucagon levels during OGTT
Glucose tolerance: Fructosamin
Fructosamin levels
Glucose tolerance: HbA1C
HbA1C levels
Glucose tolerance: Continuous glucose monitoring average
Continuous glucose monitoring for average glucose levels
Glucose tolerance: Continuous glucose monitoring glucose variability
Continuous glucose monitoring for glucose variability
Glucose tolerance: Continuous glucose monitoring time within range
Continuous glucose monitoring for time within range
Glucose absorption
Glucose absorption measured by 3-OMG concetrations during OGTT
Metabolomics
Metabolomics in plasma, urine and stool samples, measured by 1H-NMR and Liquid Chromatography-Mass Spectrometry (LC-MS).
Gut microbiota composition
The taxonomic and functional profiles of the gut microbiota (stool samples) assessed by metagenomic shotgun sequencing.
Gastrointestinal hormones secretion: GLP-1
Secretion of GLP-1 during OGTT
Gastrointestinal hormones secretion: PYY
Secretion of PYY during OGTT
Gastrointestinal hormones secretion: Ghrelin
Secretion of Ghrelin during OGTT
Gastrointestinal hormones secretion: CCK
Secretion of CCK during OGTT
Food intake
Food intake assessed with self-reported food records
Gastrointestinal tolerance
Gastrointestinal tolerance recorded by the "Gastrointestinal Symptoms Rating Scale" (GSRS), 15 items rated on 7 Point Likert-Scale, a higher score means a worse outcome. Maximum score: 90, Minimum score: 0
Body composition: fat mass
Body composition assessed by mean of bioimpedance analysis: fat mass in kg
Body composition: fat free mass
Body composition assessed by mean of bioimpedance analysis: fat free mass in kg
EryClot-Pilot Blood p-Selectin concentrations
Blood p-Selectin concentrations after consumption of test solution
EryClot-Pilot Blood Erythritol concentrations
Blood Erythritol concentrations after consumption of test solution

Full Information

First Posted
May 25, 2021
Last Updated
September 6, 2023
Sponsor
University Hospital, Basel, Switzerland
search

1. Study Identification

Unique Protocol Identification Number
NCT04966299
Brief Title
Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents
Acronym
EryAdo
Official Title
Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents: a Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 18, 2021 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
November 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Childhood and adolescence are crucial periods for prevention of obesity, as obese children are five times more likely to be obese at adulthood than lean children. To this purpose, sugar consumption should be reduced. The sugar alcohol erythritol is increasingly popular as sugar substitute in the food industry and is also recommended to diabetic patients. The substance is freely available. Recent acute studies show that erythritol has a positive influence on satiation and gastric emptying without affecting insulin and plasma glucose. In this trial, the investigators aim to assess the effect of a chronic intake of erythritol versus sucrose on insulin resistance in healthy adolescents. EryClot-Pilot: Erythritol is also produced by the human body and possibly elevated erythritol levels in the blood are an indication of an increased risk of cardiovascular disease, obesity or diabetes in the future. In a recently published study, a possible effect of erythritol on blood clotting function was described. In this in vitro experiment, increased blood clotting was observed when erythritol was added to clotting cells (platelets) in the test tube. Studies in humans on blood coagulation after administration of erythritol are missing so far. With a pilot study, the investigators study whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood coagulation function after administration of erythritol will be investigated. These preliminary tests serve to clarify the data situation so that further studies can be based on them.
Detailed Description
This trial aims to assess the effects of the daily intake of an erythritol-sweetened beverage over 5 weeks on insulin resistance, glucose tolerance and metabolism as well as on gut microbiota. Moreover, this study will also assess the effect of the above-mentioned intervention on food intake, body composition and gastrointestinal tolerance in this population. EryClot-Pilot: The aim of this pilot study is to investigate whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood clotting function after administration of erythritol will be investigated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance, Glucose Tolerance, Body Composition, Gastrointestinal Tolerance, Thrombocyte Aggregation, Blood p-Selectin, Blood Erythritol

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
EryClot-Pilot: This trial is a randomized, double-blind, crossover trial. The project set-up is single-center, national. In total, 3 volunteers will be enrolled. There will be 3 study arms.
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sucrose
Arm Type
Active Comparator
Arm Description
15 participants receive 25g sucrose per day during 5 weeks
Arm Title
Erythritol
Arm Type
Experimental
Arm Description
15 participants receive 36g eryhtritol per day during 5 weeks
Arm Title
EryClot-Pilot Erythritol
Arm Type
Experimental
Arm Description
3 participants receive 50g erythritol dissolved in 300mL water once during the visit
Arm Title
EryClot-Pilot Glucose
Arm Type
Active Comparator
Arm Description
3 participants receive 75g glucose dissolved in 300mL water once during the visit
Arm Title
EryClot-Pilot Fructose
Arm Type
Active Comparator
Arm Description
3 participants receive 25g fructose dissolved in 300mL water once during the visit
Intervention Type
Dietary Supplement
Intervention Name(s)
Eryhtritol
Other Intervention Name(s)
E968-Erythritol
Intervention Description
Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks EryClot-Pilot: Erythritol 50g dissolved in 300mL water administered once per visit
Intervention Type
Dietary Supplement
Intervention Name(s)
Sucrose
Intervention Description
Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Glucose
Intervention Description
Glucose 75g dissolved in 300mL water administered once per visit
Intervention Type
Dietary Supplement
Intervention Name(s)
Fructose
Intervention Description
Fructose 25g dissolved in 300mL water administered once per visit
Primary Outcome Measure Information:
Title
Insulin resistance
Description
Insulin resistance as measured by the HOMA Index.
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
EryClot-Pilot Thrombocyte aggregation
Description
Thrombocyte aggregation after consumption of test solution measured with a blood sample
Time Frame
Blood samples at timepoint t= 0, 30, 60, 120, 180 minutes
Secondary Outcome Measure Information:
Title
Glucose tolerance: Insulin
Description
Insulin levels during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: Glucose
Description
Glucose levels during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: C-Peptide
Description
C-peptide levels during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: Glucagon
Description
Glucagon levels during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: Fructosamin
Description
Fructosamin levels
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: HbA1C
Description
HbA1C levels
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: Continuous glucose monitoring average
Description
Continuous glucose monitoring for average glucose levels
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: Continuous glucose monitoring glucose variability
Description
Continuous glucose monitoring for glucose variability
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose tolerance: Continuous glucose monitoring time within range
Description
Continuous glucose monitoring for time within range
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Glucose absorption
Description
Glucose absorption measured by 3-OMG concetrations during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Metabolomics
Description
Metabolomics in plasma, urine and stool samples, measured by 1H-NMR and Liquid Chromatography-Mass Spectrometry (LC-MS).
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Gut microbiota composition
Description
The taxonomic and functional profiles of the gut microbiota (stool samples) assessed by metagenomic shotgun sequencing.
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Gastrointestinal hormones secretion: GLP-1
Description
Secretion of GLP-1 during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Gastrointestinal hormones secretion: PYY
Description
Secretion of PYY during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Gastrointestinal hormones secretion: Ghrelin
Description
Secretion of Ghrelin during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Gastrointestinal hormones secretion: CCK
Description
Secretion of CCK during OGTT
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Food intake
Description
Food intake assessed with self-reported food records
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Gastrointestinal tolerance
Description
Gastrointestinal tolerance recorded by the "Gastrointestinal Symptoms Rating Scale" (GSRS), 15 items rated on 7 Point Likert-Scale, a higher score means a worse outcome. Maximum score: 90, Minimum score: 0
Time Frame
Change from baseline to 3 and 5 weeks after polyol/sucrose intake
Title
Body composition: fat mass
Description
Body composition assessed by mean of bioimpedance analysis: fat mass in kg
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
Body composition: fat free mass
Description
Body composition assessed by mean of bioimpedance analysis: fat free mass in kg
Time Frame
Change from baseline to 5 weeks after polyol/sucrose intake
Title
EryClot-Pilot Blood p-Selectin concentrations
Description
Blood p-Selectin concentrations after consumption of test solution
Time Frame
Blood samples at timepoint t= 0, 30, 60, 120, 180 minutes and 24, 48 hours
Title
EryClot-Pilot Blood Erythritol concentrations
Description
Blood Erythritol concentrations after consumption of test solution
Time Frame
Blood samples at timepoint t= 0, 30, 60, 120, 180 minutes and 24, 48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
EryAdo: Inclusion Criteria: Healthy adolescents Aged 14-18 years Normal weight (BMI between 15th and 85th percentile for age and gender) Minimum weight of 45kg Regular sugar consumption >25g/d Exclusion Criteria: Severe acute or chronic diseases Pregnancy Regular intake of prebiotics Regular intake of probiotics Regular intake of pro-/prebiotic foods Antibiotics cure within 3 months preceding the present study Substance abuse Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German) Participation in another study with investigational drug within the 30 days preceding and during the present study. Pre-existing regular consumption (>1/week) of erythritol Fructose-intolerance Pre-existing diet (vegetarian, vegan, gluten-free, lactose-free, caloric restriction, etc.) EryClot-Pilot: 3 participants Inclusion criteria: Healthy participants 18-55 years upon inclusion Normal weight (BMI between 19.0-24.9 kg/m2) Informed consent signed by participant Exclusion criteria: Severe acute or chronic diseases Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening Substance abuse, smoking Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German) Participation in another study with investigational drug within the 30 days preceding and during the present study. Pre-existing regular consumption (>1/week) of erythritol Fructose-intolerance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bettina K. Wölnerhanssen, PD. MD
Phone
+ 41 61 685 86 32
Email
bettina.woelnerhanssen@claraspital.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Christin Meyer-Gerspach, PD. PhD
Phone
+41 61685 86 44
Email
annechristin.meyergerspach@unibas.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bettina K. Wölnerhanssen, PD. MD
Organizational Affiliation
St. Clara Research Ltd.
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Claraspital
City
Basel
State/Province
Basel-Stadt
ZIP/Postal Code
4002
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bettina K. Wölnerhanssen, PD. MD
Phone
+41 61 685 86 32
Email
bettina.woelnerhanssen@claraspital.ch

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents

We'll reach out to this number within 24 hrs